High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
NCT ID: NCT01976195
Last Updated: 2016-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
NCT02153060
rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
NCT01734044
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
NCT03252457
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
NCT01356511
Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)
NCT02642380
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone therapy compared to high-dose dexamethasone for the treatment of adults with ITP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thalidomide plus HD-Dexmamethasone
Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
Dexamethasone
Dexamethasone 40 mg per day, 4 consecutive days
Thalidomide
Thalidomide 150mg per day, 15 consecutive days
Dexamethasone
Dexamethasone 40 mg per day, 4 consecutive days
Dexamethasone
Dexamethasone 40 mg per day, 4 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone
Dexamethasone 40 mg per day, 4 consecutive days
Thalidomide
Thalidomide 150mg per day, 15 consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
OTHER
Anhui Medical University
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
Shenzhen Second People's Hospital
OTHER
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming Hou
Professor and Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu hospital, Shandong University
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITP-Thalidomide
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.